EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Search
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
History
History
Generalized pustular psoriasis: The Impact Beyond The Skin
An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Scouting for digital innovation
Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
World Patient Safety Day 2021
As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
COVID-19
As a research-driven company, we are part of the collective effort in fighting COVID-19. Learn more about our ongoing engagement in the fight against COVID-19
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Swine
Swine
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Cat vaccination 10 things you should know
Find out how you can keep your feline companion happy and healthy.
Heart Diseases
Heart Diseases
Schizophrenia
Schizophrenia
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Thank you for submitting your report
multistep form
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor